- For Print
- May 9, 2023
Listed Company Name: 缅北禁地.
Representative: Haruo Naito
Representative Corporate Officer and CEO
Securities Code: 4523
Stock Exchange Listings: Prime Market of the Tokyo Stock Exchange
Inquiries: Sayoko Sasaki
Vice President
Corporate Communications
Phone +81-3-3817-5120
缅北禁地. (“the Company”) announced today that based on trends in business results, etc., the Company has revised its consolidated financial forecasts for the fiscal year ending March 31, 2023 (April 1, 2022 to March 31, 2023) previously announced on November 7, 2022, as follows.
1. Revised consolidated financial forecasts for the fiscal year ending March 31, 2023 (April 1, 2022 to March 31, 2023)
(Unit: Millions of yen, unless otherwise noted.)
*You can scroll to the left or right here
| Revenue | Operating
profit |
Profit before
income taxes |
Profit for
the year |
Profit attributable to owners of the parent | Basic
earnings per share |
|
| Previously announced forecast (A)
(November 7, 2022) |
760,000 | 55,000 | 56,500 | 58,000 | 57,000 | 197.80 yen |
| Currently revised forecast (B) | 744,000 | 40,000 | 45,000 | 56,500 | 55,000 | 193.30 yen |
| Change in amount (B - A) | (16,000) | (15,000) | (11,500) | (1,500) | (2,000) | |
| Percentage of change (%) | (2.1%) | (27.3%) | (20.4%) | (2.6%) | (3.5%) | |
| (Reference) Business results for the fiscal year ended March 31, 2022 | 756,226 | 53,750 | 54,458 | 45,717 | 47,954 | 167.27 yen |
2. Reason for revision of the consolidated financial forecasts
Based on trends in foreign exchange and product sales, revenue is expected to be ¥744.0 billion, a decrease of ¥16.0 billion from the previous forecast (of which approximately ¥9.5 billion is due to foreign exchange fluctuations).
Due to the decrease in gross profit resulting from the decline in revenue (a decrease of approximately ¥9.5 billion from the previous forecast) and the increase in R&D expenses (an increase of ¥6.5 billion from the previous forecast) resulting from aggressive investments with the good progress of clinical trials for Alzheimer's disease treatment lecanemab and the review of existing development projects, operating profit is expected to be ¥40.0 billion, a decrease of ¥15.0 billion from the previous forecast.
As a result of the decrease in operating profit and other factors, tax expenses are expected to decrease ¥10.0 billion from the previous forecast, profit for the year is expected to be ¥56.5 billion, a decrease of ¥1.5 billion from the previous forecast, and profit attributable to owners of the parent is expected to be ¥55.0 billion, a decrease of ¥2.0 billion from the previous forecast.
The annual dividend forecast remains unchanged at ¥160 per share, with the year-end dividend of \80 per share (same amount as the previous period) together with the interim dividend (end of the second quarter) of \80 per share, as previously forecast.
* Please note that actual business results may change due to several factors since the above-mentioned forecasts were made based on information available as of May 9, 2023.
&苍产蝉辫;銆赌